ZAP Surgical Announces Strategic Partnership and Multi-System Order with Apollo Hospitals Enterprise Ltd. in India

ZAP Surgical Systems, Inc. today announced an agreement with Apollo Hospitals Enterprise Ltd. to acquire two ZAP-X® Gyroscopic Radiosurgery® systems. Apollo is well regarded as one of the most accomplished neurosurgery providers in India, and will become the first in South Asia to offer ZAP’s latest advance in completely non-invasive brain tumor treatments.

The agreement also aims to create a global radiosurgery center-of-excellence, namely “Apollo Brain Center,” dedicated to offering best-in-class technology and comprehensive neurosurgical care. First patient treatments with ZAP-X are expected to occur in early 2023 in New Delhi, followed by a subsequent installation in Mumbai.

Radiosurgery, also commonly referred to as SRS, is a well-established procedure for the non-invasive treatment of many primary and metastatic brain tumors, as well as select cancers of the head and neck. Often considered an alternative to costly and invasive surgical procedures, SRS is a non-invasive procedure that often provides equivalent to superior outcomes, yet requires no surgical incision, and little to no patient recovery period.

ZAP-X has transformed modern radiosurgery with a ground-breaking gyroscopic design that delivers hundreds of uniquely angled radiation beams. Combined, the myriad beams shape to the unique contours of targeted tumors with sub-millimetric precision. With this innovative approach, ZAP-X provides an enhanced ability to avoid critical structures and preserve healthy brain tissue. Additionally, where previous SRS technologies often required up to 5 patient treatments spread over multiple days, the high-precision of ZAP-X now enables many patients to be treated in a single outpatient procedure.

“With a special focus on radiosurgery for benign and malignant lesions as well as functional disorders, Apollo has always been the forerunner in introducing the latest in clinical technology to the region,” states Dr. Prathap Reddy, Founder and Chairman of Apollo Healthcare. “With intense research we zeroed in on ZAP-X based on its cutting-edge advantage over historical Cobalt-60 and robotic radiosurgery platforms. With further feedback from our neurosurgeons, we were confident that ZAP-X was the ideal technology to reinforce our standing as a best-in-class provider of neurosurgical care.”

ZAP-X is currently in clinical use at prominent institutions worldwide including Barrow Neurological Institute in Phoenix, Arizona, MedStar Georgetown Cancer Institute in Clinton, Maryland, the European Radiosurgery Center in Munich, Germany, and elsewhere. To date there are more than 30 additional ZAP-X system orders in various states of installation planning and commissioning.

“When treating the brain, especially with a complex procedure such as SRS, the tools must be highly specialized and impeccably precise,” says Dr. John R. Adler, CEO of ZAP Surgical and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. “ZAP-X looks to set new standards in treatment quality and will be a significant asset in furthering Apollo’s commitment to excellence.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy